Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 16/20 | 0.46 |
| ▸ | MAOA | P21397 | 16/20 | 0.46 |
| ▸ | MAOB | P27338 | 16/20 | 0.46 |
| ▸ | KDM4A | O75164 | 3/20 | 0.37 |
| ▸ | KDM4B | O94953 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2002653 | 0.79 | ESR2 (0.42) | ALOX5AP | |
| SCHEMBL28298445 | 0.79 | ALDH1A1 (0.44) | — | |
| SCHEMBL18642602 | 0.76 | MAOB (0.47) | KDM1AMAOAMAOBKDM4AKDM4B | |
| SCHEMBL27917474 | 0.72 | MAOB (0.47) | MAOAMAOBKDM4AKDM4BKDM4C | |
| SCHEMBL675029 | 0.71 | ESR2 (0.54) | ALOX5AP | |
| SCHEMBL6544375 | 0.70 | KDM1A (0.47) | KDM1AMAOAMAOB | |
| SCHEMBL10388101 | 0.70 | KDM4A (0.42) | MAOAMAOBKDM4AKDM4BKDM4C | |
| SCHEMBL1459227 | 0.69 | KDM1A (0.37) | KDM1AMAOAMAOBALOX5AP | |
| SCHEMBL1458849 | 0.69 | TACR1 (0.35) | KDM1AMAOAMAOBKDM4AKDM4B | |
| SCHEMBL28574683 | 0.69 | KDM1A (0.50) | KDM1AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2616493-A1 | POLYMERISATION METHOD | University College Cardiff Consultants, Ltd. (GB) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012035327-A1 | POLYMERISATION METHOD | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2012-03-22 | — | — | WO | disclosed |